Cargando…

PD-L1 blockade enhances anti-tumor efficacy of NK cells

Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors. Hence, strategies that increase PD-L1 expression and tumor infiltration should make more patients eligible for PD-1/PD-L1 blockade...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oyer, Jeremiah L., Gitto, Sarah B., Altomare, Deborah A., Copik, Alicja J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205063/ https://www.ncbi.nlm.nih.gov/pubmed/30377572 http://dx.doi.org/10.1080/2162402X.2018.1509819

Ejemplares similares

Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells
por: Pandey, Veethika, et al.
Publicado: (2016)

Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells
por: Varudkar, Namita, et al.
Publicado: (2023)

Cryopreserved PM21-Particle-Expanded Natural Killer Cells Maintain Cytotoxicity and Effector Functions In Vitro and In Vivo
por: Oyer, Jeremiah L., et al.
Publicado: (2022)

Oncolytic parainfluenza virus combines with NK cells to mediate killing of infected and non-infected lung cancer cells within 3D spheroids: role of type I and type III interferon signaling
por: Varudkar, Namita, et al.
Publicado: (2021)

Identification of a novel IL-5 signaling pathway in chronic pancreatitis and crosstalk with pancreatic tumor cells
por: Gitto, Sarah B., et al.
Publicado: (2020)

Ultrasound responsive carbon monoxide releasing micelle
por: Alghazwat, Osamah, et al.
Publicado: (2020)

TIGIT Expression on Activated NK Cells Correlates with Greater Anti-Tumor Activity but Promotes Functional Decline upon Lung Cancer Exposure: Implications for Adoptive Cell Therapy and TIGIT-Targeted Therapies
por: Hasan, Md Faqrul, et al.
Publicado: (2023)

Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells
por: Tu, Jingyao, et al.
Publicado: (2022)

Differential Expression of Polyamine Pathways in Human Pancreatic Tumor Progression and Effects of Polyamine Blockade on Tumor Microenvironment
por: Nakkina, Sai Preethi, et al.
Publicado: (2021)

Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
por: Makowska, Anna, et al.
Publicado: (2019)

Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion
por: Alvarez, Maite, et al.
Publicado: (2020)

Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin
por: Chen, Shaomeng, et al.
Publicado: (2021)

Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
por: Zahm, Christopher D., et al.
Publicado: (2021)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models
por: Mitchell, Leah A., et al.
Publicado: (2019)

Improved anti-tumor immunity and efficacy upon combination of the IDO1 inhibitor GDC-0919 with anti-PD-l1 blockade versus anti-PD-l1 alone in preclinical tumor models
por: Spahn, Jessica, et al.
Publicado: (2015)

Correction To: Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
por: Gao, Yaohui, et al.
Publicado: (2021)

Gut Microbiota: A Promising Milestone in Enhancing the Efficacy of PD1/PD-L1 Blockade Therapy
por: Zhou, Yuqing, et al.
Publicado: (2022)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Treatment with a VEGFR-2 antibody results in intra-tumor immune modulation and enhances anti-tumor efficacy of PD-L1 blockade in syngeneic murine tumor models
por: Li, Yanxia, et al.
Publicado: (2022)

Next generation of anti-PD-L1 Atezolizumab with enhanced anti-tumor efficacy in vivo
por: Li, Maohua, et al.
Publicado: (2021)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy
por: Tan, Shuguang, et al.
Publicado: (2016)

Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice
por: Qin, Wan, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer
por: Roper, Nitin, et al.
Publicado: (2021)

The Emerging Interplay Between Recirculating and Tissue-Resident Memory T Cells in Cancer Immunity: Lessons Learned From PD-1/PD-L1 Blockade Therapy and Remaining Gaps
por: Gitto, Silvia, et al.
Publicado: (2021)

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade
por: Maekawa, Naoya, et al.
Publicado: (2014)

Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines
por: Park, Ji-Eun, et al.
Publicado: (2020)

Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA
por: Redmond, William L., et al.
Publicado: (2023)

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
por: Jiang, Youhai, et al.
Publicado: (2020)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction
por: Irving, Bryan A, et al.
Publicado: (2013)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Mitomycin C enhanced the efficacy of PD-L1 blockade in non-small cell lung cancer
por: Luo, Min, et al.
Publicado: (2020)

Down Regulation of c-FLIP(L) Enhance PD-1 Blockade Efficacy in B16 Melanoma
por: Wang, Yao, et al.
Publicado: (2019)

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response
por: Rubio-Pérez, Laura, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4n9dd6a2hc8uc0081bu2o6ochc